A Phase 2 Open-label Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

Trial Profile

A Phase 2 Open-label Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Mavacamten (Primary)
  • Indications Hypertrophic cardiomyopathy
  • Focus Therapeutic Use
  • Acronyms PIONEER-HCM
  • Sponsors MyoKardia
  • Most Recent Events

    • 07 Aug 2017 According to a MyoKardia media release, after reviewing safety data, the Independent Data Monitoring Committee (IDMC) recommended continuation of the study.
    • 07 Aug 2017 According to a MyoKardia media release, the second, low-dose patient cohort has completed enrollment, top-line data from this cohort is expected in in the first quarter of 2018.
    • 07 Aug 2017 According to a MyoKardia media release, Stephen Heitner director of the HCM Clinic at Oregon Health and Science University Knight Cardiovascular Institute is the lead investigator of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top